ISDA: 2XJX

Deposition Date 2010-07-06

Release Date 2010-08-11

Last Version Date 2024-05-08

Entry Detail

PDB ID:

2XJX

Keywords:

CHAPERONE

Title:

Structure of HSP90 with small molecule inhibitor bound

Biological Source:

Source Organism(s):

HOMO SAPIENS (Taxon ID: 9606)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.66 Å

R-Value Free:

0.20

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:HEAT SHOCK PROTEIN HSP 90-ALPHA
Gene (Uniprot):HSP90AA1
Chain IDs:A
Chain Length:249
Number of Molecules:1
Biological Source:HOMO SAPIENS

UniProt ID:P07900 Pfam ID:PF13589 EC:3.6.4.10

Ligand Molecules

XJX

Primary Citation

Discovery of (2,4-Dihydroxy-5-Isopropylphenyl)-[5-(4-Methylpiperazin-1-Ylmethyl)-1,3-Dihydroisoindol-2-Yl]Methanone (at13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.

Woodhead, A.J, Angove, H, Carr, M.G, Chessari, G, Congreve, M, Coyle, J.E, Cosme, J, Graham, B, Day, P.J, Downham, R, Fazal, L, Feltell, R, Figueroa, E, Frederickson, M, Lewis, J, Mcmenamin, R, Murray, C.W, O'Brien, M.A, Parra, L, Patel, S, Phillips, T, Rees, D.C, Rich, S, Smith, D.M, Trewartha, G, Vinkovic, M, Williams, B, Woolford, A.J.Show

J.Med.Chem. 53 5956 ? (2010)

PMID: 20662534 DOI: 10.1021/JM100060B

Abstact

Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form